NPORT-EX 2 NPORT_2773690793169507.htm BlackRock Future Health ETF

Schedule of Investments  (unaudited)

October 31, 2020

   

BlackRock Future Health ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

 

Biotechnology — 37.5%

 

Acceleron Pharma Inc.(a)

    738     $ 77,180  

Agios Pharmaceuticals Inc.(a)

    1,038       41,593  

Akeso Inc.(a)(b)

    6,000       18,801  

Akouos Inc.(a)

    655       12,713  

Alexion Pharmaceuticals Inc.(a)

    396       45,595  

Allakos Inc.(a)

    524       49,848  

Alnylam Pharmaceuticals Inc.(a)

    648       79,685  

ALX Oncology Holdings Inc.(a)

    672       26,551  

Amicus Therapeutics Inc.(a)

    1,044       18,614  

Annexon Inc.(a)

    432       8,990  

Apellis Pharmaceuticals Inc.(a)

    402       12,824  

Applied Molecular Transport Inc.(a)

    390       11,462  

Arcutis Biotherapeutics Inc.(a)

    366       6,522  

Arena Pharmaceuticals Inc.(a)

    354       30,345  

Argenx SE, ADR(a)

    282       69,973  

Arrowhead Pharmaceuticals Inc.(a)

    198       11,345  

Avidity Biosciences Inc.(a)

    864       21,367  

Beam Therapeutics Inc.(a)

    396       13,531  

Biohaven Pharmaceutical Holding Co. Ltd.(a)

    205       15,879  

BioMarin Pharmaceutical Inc.(a)

    474       35,280  

Blueprint Medicines Corp.(a)

    180       18,410  

C4 Therapeutics Inc.(a)

    797       19,726  

CareDx Inc.(a)

    534       26,193  

ChemoCentryx Inc.(a)

    178       8,544  

Cytokinetics Inc.(a)

    604       9,283  

Deciphera Pharmaceuticals Inc.(a)

    192       11,149  

Dicerna Pharmaceuticals Inc.(a)

    942       19,773  

Eidos Therapeutics Inc.(a)

    282       19,999  

Fate Therapeutics Inc.(a)

    264       11,722  

FibroGen Inc.(a)

    378       14,508  

Forma Therapeutics Holdings Inc.(a)

    1,272       54,849  

Galecto Inc.(a)

    1,297       19,455  

Genetron Holdings Ltd.(a)

    2,280       23,028  

Genmab A/S(a)

    510       169,882  

Genmab A/S, ADR(a)

    1,620       54,529  

Global Blood Therapeutics Inc.(a)

    192       10,153  

Grifols SA

     1,650       44,571  

Immunovant Inc.(a)

    600       26,172  

Intellia Therapeutics Inc.(a)

    342       8,187  

Iovance Biotherapeutics Inc.(a)

    1,008       35,965  

Kadmon Holdings Inc.(a)

    3,420       11,628  

Karyopharm Therapeutics Inc.(a)

    954       14,138  

Keros Therapeutics Inc.(a)

    498       27,689  

Kodiak Sciences Inc.(a)

    420       38,140  

Krystal Biotech Inc.(a)

    384       16,508  

Kymera Therapeutics Inc.(a)

    636       22,890  

Mersana Therapeutics Inc.(a)

    3,666       66,061  

Mirati Therapeutics Inc.(a)

    213       46,251  

Neurocrine Biosciences Inc.(a)

    408       40,257  

Nkarta Inc.(a)

    990       28,423  

ORIC Pharmaceuticals Inc.(a)

    462       9,933  

PMV Pharmaceuticals Inc.(a)

    1,134       39,747  

Praxis Precision Medicines Inc.(a)

    1,002       35,070  

Prothena Corp. PLC(a)

    852       9,295  

PTC Therapeutics Inc.(a)

    510       26,617  

Rapt Therapeutics Inc.(a)

    444       12,761  

Regeneron Pharmaceuticals Inc.(a)

    162       88,057  

Retrophin Inc.(a)

    924       18,702  
Security   Shares     Value  
Biotechnology (continued)            

Sage Therapeutics Inc.(a)

    372     $ 27,297  

Sarepta Therapeutics Inc.(a)

    168       22,833  

Seagen Inc.(a)

    1,170       195,156  

Seres Therapeutics Inc.(a)

    876       24,432  

Stoke Therapeutics Inc.(a)

    240       9,214  

Taysha Gene Therapies Inc.(a)

    420       8,736  

TCR2 Therapeutics Inc.(a)

    534       10,504  

Twist Bioscience Corp.(a)

    570       43,685  

United Therapeutics Corp.(a)

    138       18,524  

Vertex Pharmaceuticals Inc.(a)

    205       42,714  

Vir Biotechnology Inc.(a)

    312       9,809  

Zai Lab Ltd., ADR(a)

    456       37,415  

Zentalis Pharmaceuticals Inc.(a)

    534       21,141  

Zymeworks Inc.(a)

    594       23,237  
   

 

 

  
      2,261,060  

Diversified Financial Services — 0.4%

 

Eucrates Biomedical Acquisition Corp.(a)

    1,857       18,570  

Helix Acquisition Corp.(a)

    445       4,570  
   

 

 

  
      23,140  

Health Care Equipment & Supplies — 27.7%

 

ABIOMED Inc.(a)

    192       48,361  

Alcon Inc.(a)

    1,830       104,017  

Baxter International Inc.

     1,464       113,563  

Cardiovascular Systems Inc.(a)

    396       14,117  

Coloplast A/S, Class B

     48       7,005  

ConvaTec Group PLC(b)

    10,962       25,612  

Demant A/S(a)

    1,644       51,778  

Eargo Inc.(a)

    400       13,860  

Edwards Lifesciences Corp.(a)

    660       47,315  

Envista Holdings Corp.(a)

    918       24,254  

GN Store Nord A/S

     1,482       106,592  

Haemonetics Corp.(a)

    648       65,506  

Hill-Rom Holdings Inc.

     342       31,146  

Insulet Corp.(a)

    336       74,676  

Intuitive Surgical Inc.(a)

    174       116,072  

Masimo Corp.(a)

    558       124,892  

Nevro Corp.(a)

    588       87,736  

NuVasive Inc.(a)

    324       14,395  

Penumbra Inc.(a)

    264       68,912  

Pulmonx Corp.(a)

    229       9,632  

ResMed Inc.

     414       79,463  

Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Class A

     900       51,987  

Silk Road Medical Inc.(a)

    708       42,905  

Sonova Holding AG, Registered(a)

    150       35,595  

STERIS PLC

     324       57,410  

Straumann Holding AG, Registered

     78       81,357  

Tandem Diabetes Care Inc.(a)

    600       65,400  

Teleflex Inc.

     336       106,925  
   

 

 

  
      1,670,483  

Health Care Providers & Services — 10.0%

 

Addus HomeCare Corp.(a)

    102       9,952  

Amedisys Inc.(a)

    540       139,860  

Amplifon SpA(a)

    1,518       55,187  

Centene Corp.(a)

    846       49,999  

Chemed Corp.

     60       28,699  

Encompass Health Corp.

     972       59,593  

Humana Inc.

     192       76,662  

Jinxin Fertility Group Ltd.(b)

    48,000       58,183  
 

 

 

    

   1

Schedule of Investments  (unaudited) (continued)

October 31, 2020

   

BlackRock Future Health ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Health Care Providers & Services (continued)            

LHC Group Inc.(a)

    582     $ 126,032  
   

 

 

  
      604,167  
Health Care Technology — 2.5%            

American Well Corp., Class A(a)

    1,566       40,418  

GoodRx Holdings Inc., Class A(a)

    162       7,839  

Livongo Health Inc.(a)(c)

    480       67,090  

Teladoc Health Inc.(a)

    174       34,184  
   

 

 

  
      149,531  
Insurance — 0.9%            

eHealth Inc.(a)

    438       29,394  

Selectquote Inc.(a)

    1,308       22,524  
   

 

 

  
      51,918  
Life Sciences Tools & Services — 10.8%            

10X Genomics Inc., Class A(a)

    114       15,607  

Avantor Inc.(a)

    1,800       41,886  

Berkeley Lights Inc.(a)

    798       57,911  

Charles River Laboratories International Inc.(a)

    216       49,183  

Gerresheimer AG

     366       36,793  

Illumina Inc.(a)

    84       24,587  

IQVIA Holdings Inc.(a)

    342       52,665  

Lonza Group AG, Registered

     84       50,883  

PPD Inc.(a)

    3,996       131,388  

WuXi AppTec Co. Ltd., Class H(b)

    6,000       95,553  

Wuxi Biologics Cayman Inc.(a)(b)

    3,500       97,758  
   

 

 

  
      654,214  
Pharmaceuticals — 7.7%            

Astellas Pharma Inc.

     2,400       32,944  

Atea Pharmaceuticals Inc.

     535       16,232  

Chugai Pharmaceutical Co. Ltd.

     700       26,925  

Eisai Co. Ltd.

     200       15,475  

Hansoh Pharmaceutical Group Co. Ltd.(a)(b)

    24,000       106,927  

Harmony Biosciences Holdings Inc.(a)

    228       8,869  
Security   Shares     Value  
Pharmaceuticals (continued)            

Horizon Therapeutics PLC(a)

    396     $ 29,672  

Merck KGaA

     468       69,316  

MyoKardia Inc.(a)

    90       20,118  

Nektar Therapeutics(a)

    834       13,211  

Relmada Therapeutics Inc.(a)

    618       19,115  

Royalty Pharma PLC, Class A

     336       12,331  

UCB SA

     918       90,572  
   

 

 

  
      461,707  
   

 

 

  

Total Common Stocks — 97.5%
(Cost: $5,880,996)

       5,876,220  
   

 

 

  

Short-Term Investments

    
Money Market Funds — 2.3%            

BlackRock Cash Funds: Treasury, SL Agency Shares, 0.04%(d)(e)

     140,000       140,000  
   

 

 

  

Total Short-Term Investments — 2.3%
(Cost: $140,000)

       140,000  
   

 

 

  

Total Investments in Securities — 99.8%
(Cost: $6,020,996)

       6,016,220  

Other Assets, Less Liabilities — 0.2%

       14,906  
   

 

 

  

Net Assets — 100.0%

     $ 6,031,126  
   

 

 

  

 

(a) 

Non-income producing security.

(b)

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(c) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(d)

Affiliate of the Fund.

(e) 

Annualized 7-day yield as of period-end.

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2020 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   

Value at

09/29/20(a)

     

Purchases

at Cost

      Proceeds
from Sales		      Net Realized
Gain (Loss)		     

Change in

Unrealized

Appreciation

(Depreciation)

     

Value at

10/31/20

     

Shares

Held at

10/31/20

      Income     

Capital

Gain

Distributions

from

Underlying

Funds

  

BlackRock Cash Funds: Treasury, SL Agency Shares

    $ —      $ 140,000 (b)     $ —      $ —      $ —      $ 140,000        140,000      $ 6      $ —  
           

 

 

     

 

 

     

 

 

        

 

 

     

 

 

  

 

  (a) 

The Fund commenced operations on September 29, 2020.

 
  (b) 

Represents net amount purchased (sold).

 

Fair Value Measurements

Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.

 

 

2  

    

Schedule of Investments  (unaudited) (continued)

October 31, 2020

    BlackRock Future Health ETF

 

Fair Value Measurements (continued)

The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of October 31, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Investments

                  

Assets

                  

Common Stocks

    $ 5,809,130        $ —        $  67,090        $ 5,876,220  

Money Market Funds

      140,000          —          —          140,000  
  

 

 

       

 

 

       

 

 

       

 

 

  
   $ 5,949,130        $ —        $  67,090        $ 6,016,220  
  

 

 

       

 

 

       

 

 

       

 

 

  

The following table includes a rollforward for the period ended October 31, 2020 of investments whose values are classified as Level 3 as of the beginning or end of the period.

 

      Common
Stocks		  

Balance at beginning of period(a)

   $ —  

Realized gain (loss) and change in unrealized appreciation/depreciation

      506  

Purchases

      66,584  

Sales

      —  

Transfers in

      —  

Transfers out

      —  
  

 

 

  

Balance at end of period

    $ 67,090  
  

 

 

  

Net change in unrealized appreciation/depreciation on investments still held at end of period

    $ 506  
  

 

 

  

 

  (a)

The Fund commenced operations on September 29, 2020.

 

The Fund’s investments that are categorized as Level 3 were valued utilizing a single broker quote without adjustment. Such valuations are based on unobservable inputs. A significant change in third party information could result in a significantly lower or higher value of such Level 3 investments.

Portfolio Abbreviations - Equity

ADR American Depositary Receipt

 

 

    

   3